Insider Cluster (2 insiders) ·Filed Jun 25, 2026

APGE

Apogee Therapeutics, Inc.
NEUTRAL
Impact 6/10
Horizonweeks Processed3mo ago
Insider cluster: 2 insiders, $14.1M total
Actionable Insight • Neutral

Insider sales post-merger announcement are common and not necessarily bearish, but monitor any unusual patterns or changes in deal sentiment. The merger agreement appears to be the main catalyst; focus on stockholder vote and regulatory clearances.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+20d
APGE ▲ +1.19% at T+20d
NEUTRAL call ✓ call won +1.19% · α vs SPY +0.66% · entry $132.68 → $134.26
Next anchor: T+60d due 14d ago
Entry anchored
Jun 24, 03:59 PM ET
via exchange tick
T+1d
-0.10%
call -0.10% · α +0.63%
$132.55
settled 3mo ago
T+5d
+0.07%
call +0.07% · α -1.49%
$132.77
settled 3mo ago
T+20d
+1.19%
call +1.19% · α +0.66%
$134.26
settled 2mo ago
T+60d
—
call — · α —
—
due 14d ago

Price Chart

Loading chart...

Executive Summary

Two top insiders (CEO and CMO) sold a total of $14.1M in open-market transactions on June 22, 2026, just days after the company announced a merger agreement with AbbVie. The sales represent 0.14% of market cap and are likely routine monetization ahead of the deal close, but the timing draws attention.

Key Financial Metrics

Direction
selling
Total Value
$14.1M
Insiders
2

Key Facts

  • CEO Michael Thomas Henderson sold 80,000 shares at $132.54 (~$10.6M) on June 22.
  • CMO Carl Dambkowski sold 26,400 shares at $132.60 (~$3.5M) on June 22.
  • Total insider sales of $14.1M represent 0.14% of APGE's $10B market cap.
  • Sales occurred 4 days after the June 18 merger agreement with AbbVie (via Andor entities).

Financial Impact

$14.1M in insider sales, representing 0.14% of market cap

insider ownershipshare float

Risk Factors

  • Additional insider sales could erode confidence in deal completion.
  • Regulatory or stockholder approval delays could affect timeline.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
80% bullish (25 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-APGE-1782345739974
31 reports for APGE
Performance horizon
93% Hit rate 14 of 15 directional calls best @ T+60▲ +73.31%May 27, 2026
Filters
Rows
Reports for APGE — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
15-12G
NEUTRAL ★ 4/10
—awaiting T+5——
Sep 3, 2026
29d ago
25-NSE
BULLISH ★ 8/10
$135.06 awaiting T+5awaiting T+5——
Sep 3, 2026
29d ago
8-K
BULLISH ★ 8/10
$135.06 awaiting T+5awaiting T+5——
Aug 11, 2026
7w ago
8-K
BULLISH ★ 7/10
$134.55 $134.71▲ +0.12%▲ +0.56%—
Aug 10, 2026
7w ago
8-K
BULLISH ★ 8/10
$134.65 $134.59▼ −0.04%▲ +0.00%—
Aug 10, 2026
7w ago
Press Release
BULLISH ★ 8/10
$134.65 $134.59▼ −0.04%▲ +0.00%—
Aug 6, 2026
8w ago
Institutional Cluster
MIXED ★ 5/10
$134.49 $134.45▼ −0.03%▼ −1.24%—
Aug 3, 2026
8w ago
DEFA14A
BULLISH ★ 5/10
$134.19 $134.69▲ +0.37%▲ +0.47%—
Jul 11, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$133.82 $134.00▲ +0.13%▲ +0.92%—
Jun 26, 2026
13w ago
DEFA14A
BULLISH ★ 6/10
$132.61 $133.50▲ +0.67%▼ −0.72%—
Showing 10 of 31

US Market Status

Market Open — Closes in 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 25, 2026